|
|
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
|
|
|
TherapeuticsMD Announces First Quarter 2022 Financial Results
|
|
|
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
|
|
|
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
|
|
|
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
|
|
|
TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx
|
|
|
TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022
|
